PAVmed Inc. (PAVM)
NASDAQ: PAVM · Real-Time Price · USD
1.050
+0.010 (0.96%)
Nov 4, 2024, 4:00 PM EST - Market closed
PAVmed Revenue
PAVmed had revenue of $979.00K in the quarter ending June 30, 2024, with 489.76% growth. This brings the company's revenue in the last twelve months to $3.83M, up 378.63% year-over-year. In the year 2023, PAVmed had annual revenue of $2.45M with 550.40% growth.
Revenue (ttm)
$3.83M
Revenue Growth
+378.63%
P/S Ratio
2.29
Revenue / Employee
$35,785
Employees
107
Market Cap
10.93M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Star Equity Holdings | 47.15M |
Kiora Pharmaceuticals | 16.02M |
Dominari Holdings | 9.51M |
RedHill Biopharma | 3.71M |
Alterity Therapeutics | 2.68M |
Senti Biosciences | 338.00K |
BioRestorative Therapies | 174.10K |
PAVM News
- 4 days ago - PAVmed to Hold a Business Update Conference Call and Webcast on November 14, 2024 - PRNewsWire
- 5 days ago - Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 13, 2024 - PRNewsWire
- 20 days ago - Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test - PRNewsWire
- 25 days ago - PAVmed Subsidiary, Veris Health, Awarded $1.8 Million NIH Grant to Enhance Cancer Care - PRNewsWire
- 26 days ago - Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit - PRNewsWire
- 27 days ago - Lucid Diagnostics to Join Global Medtech Leaders at The MedTech Conference 2024 - PRNewsWire
- 5 weeks ago - American Foregut Society's 2024 Annual Meeting to Highlight Lucid Diagnostics' EsoGuard Esophageal Precancer Test - PRNewsWire
- 7 weeks ago - PAVmed Announces Efforts to Regain Compliance with Nasdaq Listing Requirements - PRNewsWire